CA2499390C - Kits and methods for assessing skin health - Google Patents
Kits and methods for assessing skin health Download PDFInfo
- Publication number
- CA2499390C CA2499390C CA2499390A CA2499390A CA2499390C CA 2499390 C CA2499390 C CA 2499390C CA 2499390 A CA2499390 A CA 2499390A CA 2499390 A CA2499390 A CA 2499390A CA 2499390 C CA2499390 C CA 2499390C
- Authority
- CA
- Canada
- Prior art keywords
- occurrence
- residue
- polymorphism
- gene
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 93
- 230000036559 skin health Effects 0.000 title claims abstract description 82
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 306
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 226
- 102000054765 polymorphisms of proteins Human genes 0.000 claims abstract description 154
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 141
- 208000017520 skin disease Diseases 0.000 claims abstract description 67
- 239000002773 nucleotide Substances 0.000 claims abstract description 14
- 208000035475 disorder Diseases 0.000 claims description 218
- 125000000539 amino acid group Chemical group 0.000 claims description 74
- 108020004705 Codon Proteins 0.000 claims description 68
- 108091034117 Oligonucleotide Proteins 0.000 claims description 54
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 33
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 32
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 30
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 30
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 29
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 28
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 27
- 230000001086 cytosolic effect Effects 0.000 claims description 25
- 108020002908 Epoxide hydrolase Proteins 0.000 claims description 24
- 102000005486 Epoxide hydrolase Human genes 0.000 claims description 23
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 22
- 230000002438 mitochondrial effect Effects 0.000 claims description 22
- 101710112368 Glutathione S-transferase P 1 Proteins 0.000 claims description 21
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 20
- 108010053835 Catalase Proteins 0.000 claims description 18
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 18
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 claims description 18
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 18
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 18
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 18
- 239000004474 valine Substances 0.000 claims description 18
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 17
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims description 17
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 16
- 102100030943 Glutathione S-transferase P Human genes 0.000 claims description 16
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims description 13
- 238000000137 annealing Methods 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 12
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 12
- 229960000310 isoleucine Drugs 0.000 claims description 12
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 11
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 10
- 108010002998 NADPH Oxidases Proteins 0.000 claims description 8
- 102000004722 NADPH Oxidases Human genes 0.000 claims description 8
- 102000016938 Catalase Human genes 0.000 claims description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 7
- 108010007843 NADH oxidase Proteins 0.000 claims description 7
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 7
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- 235000004279 alanine Nutrition 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 claims description 2
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims 9
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims 6
- 241000282412 Homo Species 0.000 abstract description 7
- 238000013077 scoring method Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 34
- 235000018102 proteins Nutrition 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 18
- 229910052760 oxygen Inorganic materials 0.000 description 18
- 239000001301 oxygen Substances 0.000 description 18
- 108700026244 Open Reading Frames Proteins 0.000 description 16
- 230000008859 change Effects 0.000 description 14
- 235000016709 nutrition Nutrition 0.000 description 14
- 239000003009 skin protective agent Substances 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 231100000331 toxic Toxicity 0.000 description 13
- 230000002588 toxic effect Effects 0.000 description 13
- 108091026890 Coding region Proteins 0.000 description 10
- 102000003849 Cytochrome P450 Human genes 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000036542 oxidative stress Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 108020005029 5' Flanking Region Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 108010070675 Glutathione transferase Proteins 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 239000013615 primer Substances 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000005720 Glutathione transferase Human genes 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 230000033616 DNA repair Effects 0.000 description 4
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 4
- 206010071602 Genetic polymorphism Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 231100001231 less toxic Toxicity 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 230000004792 oxidative damage Effects 0.000 description 4
- 230000037075 skin appearance Effects 0.000 description 4
- 241000212314 Foeniculum Species 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- 241001267511 Pikea Species 0.000 description 3
- 229960004308 acetylcysteine Drugs 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 101150008380 gstp1 gene Proteins 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- -1 hydroxyl radicals Chemical class 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000015724 Trifolium pratense Nutrition 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 235000013526 red clover Nutrition 0.000 description 2
- 230000019254 respiratory burst Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- PDEJECFRCJOMEN-UHFFFAOYSA-N 4-hydroxy-3alpha,4,5,8,9,11alpha-hexahydro-6,10-dimethyl-3-methylene-cyclodeca[b]furan-2(3H)-one Natural products OC1CC(C)=CCCC(C)=CC2OC(=O)C(=C)C21 PDEJECFRCJOMEN-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000016532 chronic granulomatous disease Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- WJZHMLNIAZSFDO-UHFFFAOYSA-N manganese zinc Chemical compound [Mn].[Zn] WJZHMLNIAZSFDO-UHFFFAOYSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/247,935 | 2002-09-20 | ||
| US10/247,935 US7211383B2 (en) | 2001-04-05 | 2002-09-20 | Kits and methods for assessing skin health |
| PCT/US2003/029529 WO2004026107A2 (en) | 2002-09-20 | 2003-09-19 | Kits and methods for assessing skin health |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2499390A1 CA2499390A1 (en) | 2004-04-01 |
| CA2499390C true CA2499390C (en) | 2013-08-20 |
Family
ID=32028981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2499390A Expired - Fee Related CA2499390C (en) | 2002-09-20 | 2003-09-19 | Kits and methods for assessing skin health |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7211383B2 (enExample) |
| EP (1) | EP1581094A4 (enExample) |
| JP (3) | JP2006513699A (enExample) |
| KR (1) | KR20050057525A (enExample) |
| AU (1) | AU2003275038B2 (enExample) |
| CA (1) | CA2499390C (enExample) |
| WO (1) | WO2004026107A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7054758B2 (en) * | 2001-01-30 | 2006-05-30 | Sciona Limited | Computer-assisted means for assessing lifestyle risk factors |
| US20020146698A1 (en) * | 2001-04-05 | 2002-10-10 | Genelink, Inc. | Kits and methods for assessing oxidative stress |
| US7211383B2 (en) * | 2001-04-05 | 2007-05-01 | Genelink, Inc. | Kits and methods for assessing skin health |
| FI20040227L (fi) * | 2004-02-13 | 2005-08-14 | Jurilab Ltd Oy | Menetelmä syövän, sepelvaltimotaudin ja aivohalvauksen riskin havaitsemiseksi |
| CN100412208C (zh) * | 2006-04-07 | 2008-08-20 | 甄二真 | 基于基因多态性的皮肤美容保健方法 |
| WO2009127073A1 (de) * | 2008-04-18 | 2009-10-22 | Gen Sod2 Foundation | Auf ein individuum abgestimmte kosmetikzubereitung und verfahren zu deren herstellung |
| US20100304373A1 (en) * | 2008-08-14 | 2010-12-02 | Ricciardi Robert P | Methods for Assessing the Susceptibility of a Human to Diminished Health and Wellness |
| KR101109043B1 (ko) * | 2008-12-30 | 2012-02-09 | 사회복지법인 삼성생명공익재단 | 각질세포 또는 혈청 유래의 아토피성 피부질환 마커 |
| JP2011115098A (ja) * | 2009-12-04 | 2011-06-16 | Nippon Menaade Keshohin Kk | 加齢による皮膚明度の低下を予測する皮膚評価方法 |
| GB2493141A (en) * | 2011-07-19 | 2013-01-30 | Gene Onyx Ltd | Method of selecting a product using a DNA sample |
| KR101803980B1 (ko) * | 2011-08-03 | 2017-12-04 | 주식회사 엘지생활건강 | 민감성 피부 타입 유전자 다형성 마커 및 이의 용도 |
| GB2497766A (en) * | 2011-12-20 | 2013-06-26 | Gene Onyx Ltd | Snp analysis to determine efficacy of skin care product |
| KR20160075501A (ko) * | 2013-09-25 | 2016-06-29 | 더 프록터 앤드 갬블 캄파니 | 피부 케어 상담을 위한 방법 및 시스템 |
| JP6328903B2 (ja) * | 2013-10-10 | 2018-05-23 | ジェネシスヘルスケア株式会社 | 皮膚関連遺伝子に基づく肌におけるリスク判別システム |
| CN108048423B (zh) * | 2018-01-15 | 2020-05-08 | 江南大学 | 一种催化活性提高的菜豆环氧化物水解酶突变体及其应用 |
| KR102346186B1 (ko) * | 2019-12-23 | 2022-01-03 | 주식회사 테라젠바이오 | 피부 민감 위험도 예측용 바이오마커 및 이의 용도 |
| KR20220137382A (ko) * | 2021-04-02 | 2022-10-12 | 주식회사 엘지생활건강 | 주름 피부 타입 판단용 유전자 다형성 마커 및 이의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3616923A1 (de) | 1986-05-20 | 1987-11-26 | Nattermann A & Cie | Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on |
| US6013431A (en) | 1990-02-16 | 2000-01-11 | Molecular Tool, Inc. | Method for determining specific nucleotide variations by primer extension in the presence of mixture of labeled nucleotides and terminators |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| CA2139667C (en) | 1992-07-06 | 2005-03-29 | Spencer B. Farr | Methods and diagnostic kits for determining toxicity utilizing bacterial stress promoters fused to reporter genes |
| US5643623A (en) | 1995-06-07 | 1997-07-01 | Mars Incorporated | Health food product and its uses |
| US6291171B1 (en) | 1995-11-15 | 2001-09-18 | Robert P. Ricciardi | Kit for the non-invasive identification and collection of DNA |
| US5891622A (en) | 1996-09-30 | 1999-04-06 | Oxford Biomedical Research, Inc. | Assessment of oxidative stress in vivo |
| US5955111A (en) | 1996-10-08 | 1999-09-21 | Hartford Hospital | Methods and compositions for inducing production of stress proteins |
| US5920634A (en) * | 1996-11-13 | 1999-07-06 | Chiquette; Grace Rojan | Activatable audio advertising display standard |
| JP3381053B2 (ja) | 1996-11-29 | 2003-02-24 | 日研フード株式会社 | 酸化的ストレス判断解析表 |
| US6133039A (en) | 1998-02-09 | 2000-10-17 | Washinton University | In vivo method for determination of oxidative stress |
| US20020146698A1 (en) | 2001-04-05 | 2002-10-10 | Genelink, Inc. | Kits and methods for assessing oxidative stress |
| EP1386001A4 (en) * | 2001-04-05 | 2005-07-20 | Genelink Inc | KITS AND METHOD FOR ASSESSING OXIDATIVE STRESS |
| US7211383B2 (en) | 2001-04-05 | 2007-05-01 | Genelink, Inc. | Kits and methods for assessing skin health |
-
2002
- 2002-09-20 US US10/247,935 patent/US7211383B2/en not_active Expired - Lifetime
-
2003
- 2003-09-19 CA CA2499390A patent/CA2499390C/en not_active Expired - Fee Related
- 2003-09-19 KR KR1020057004865A patent/KR20050057525A/ko not_active Ceased
- 2003-09-19 AU AU2003275038A patent/AU2003275038B2/en not_active Ceased
- 2003-09-19 WO PCT/US2003/029529 patent/WO2004026107A2/en not_active Ceased
- 2003-09-19 JP JP2004538253A patent/JP2006513699A/ja not_active Withdrawn
- 2003-09-19 EP EP03759308A patent/EP1581094A4/en not_active Withdrawn
-
2007
- 2007-03-30 US US11/731,180 patent/US8313930B2/en not_active Expired - Fee Related
-
2010
- 2010-07-08 JP JP2010155397A patent/JP2010263906A/ja active Pending
-
2012
- 2012-11-05 US US13/668,842 patent/US20130130247A1/en not_active Abandoned
-
2013
- 2013-08-05 JP JP2013161944A patent/JP2013240351A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006513699A (ja) | 2006-04-27 |
| US20130130247A1 (en) | 2013-05-23 |
| EP1581094A4 (en) | 2008-04-23 |
| EP1581094A2 (en) | 2005-10-05 |
| US7211383B2 (en) | 2007-05-01 |
| WO2004026107A3 (en) | 2005-12-22 |
| AU2003275038B2 (en) | 2009-09-03 |
| WO2004026107A2 (en) | 2004-04-01 |
| CA2499390A1 (en) | 2004-04-01 |
| JP2010263906A (ja) | 2010-11-25 |
| US8313930B2 (en) | 2012-11-20 |
| US20070178518A1 (en) | 2007-08-02 |
| JP2013240351A (ja) | 2013-12-05 |
| KR20050057525A (ko) | 2005-06-16 |
| US20030073612A1 (en) | 2003-04-17 |
| AU2003275038A1 (en) | 2004-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8313930B2 (en) | Kits and methods for assessing skin health | |
| Sentı́ et al. | Relationship of age-related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonase1 gene: the REGICOR study | |
| Adams et al. | Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction | |
| JP2010263906A5 (enExample) | ||
| US20140066327A1 (en) | Kits and Methods for Assessing Oxidative Stress | |
| Parıldar-Karpuzoğlu et al. | Single nucleotide polymorphisms in base-excision repair genes hOGG1, APE1 and XRCC1 do not alter risk of Alzheimer's disease | |
| Patel et al. | Analysis of the pattern, alliance and risk of rs1799752 (ACE I/D polymorphism) with essential hypertension | |
| Hashimoto et al. | The breakpoint cluster region gene on chromosome 22q11 is associated with bipolar disorder | |
| Bialecka et al. | Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson’s disease | |
| Nagy et al. | Schöpf-Schulz-Passarge syndrome resulting from a homozygous nonsense mutation in WNT10A | |
| AU2002309543B2 (en) | Kits and methods for assessing oxidative stress | |
| Liu et al. | Independent occurrence of somatic mutations in mitochondrial DNA of human skin from subjects of various ages | |
| AU2002309543A1 (en) | Kits and methods for assessing oxidative stress | |
| Kono et al. | Exclusion of linkage between dyschromatosis symmetrica hereditaria and chromosome 9 | |
| US20120164647A1 (en) | Methods for assessing the susceptibility of a human to diminished health and wellness | |
| Muiras et al. | Defending genomic stability over life span: a proposed role for PARP-1 | |
| Smith et al. | Melanocortin 1 receptor (MC1R) genotype influences erythemal sensitivity to psoralen–ultraviolet A photochemotherapy | |
| Fortes et al. | Polymorphisms of GSTM1 and GSTT1, sun exposure and the risk of melanoma: a case-control study | |
| Kotze et al. | Molecular analysis reveals a high mutation frequency in the first untranslated exon of the PPOX gene and largely excludes variegate porphyria in a subset of clinically affected Afrikaner families | |
| Abdel Rasol et al. | The effect of catalase enzyme gene polymorphism A-21T (rs7943316) on epilepsy and its drug resistance after hypoxic ischemic brain injury | |
| Cilingir et al. | Glutathione S-Transferases M1/T1 and P1 Polymorphisms in Patients with Alopecia Areata | |
| US20090081683A1 (en) | Kits and Methods for Assessing the Coenzyme Q Reducing Status of a Patient, Including a Patient Ingesting a Statin | |
| US20090053343A1 (en) | Kits and Methods for Assessing Leptin-Mediated Lipid Metabolism | |
| Cilingir et al. | Glutathıone S-Transferases M1/T1 and P1 Polymorphisms in Patıents with Alopecia Areata | |
| Mitrofanov et al. | Frequency of the 735G→ A mutation of the 5′-splice donor site of intron 14 of the dihydropyrimidine dehydrogenase gene (DPYD) in residents of novosibirsk region (Russia) as revealed with fluorescent oligonucleotides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20150921 |